Nektar Therapeutics Announces Proposed Public Offering

Core Viewpoint - Nektar Therapeutics has initiated an underwritten public offering of its common stock and pre-funded warrants, with a potential additional 15% of shares available for underwriters [1][2] Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with all shares being offered by Nektar [1] - Nektar plans to use the net proceeds for general corporate purposes, including research, development, and manufacturing costs [2] - Jefferies and Piper Sandler are acting as joint bookrunning managers for the offering [2] Group 2: Regulatory Information - The offering is conducted under a shelf registration statement filed with the SEC on March 28, 2025, and declared effective on April 1, 2025 [3] - A preliminary prospectus supplement will be filed with the SEC and will be available on their website [4] Group 3: Company Overview - Nektar Therapeutics is focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG) [6] - The company is evaluating several drug candidates in clinical trials, including NKTR-255, an investigational IL-15 receptor agonist [6]